ANN ARBOR, Mich., Dec. 07, 2020 — Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that, with the hiring of Debra Rock to lead the Company’s Marketing Department, its internal commercial leadership team is complete.
Joining Zomedica as Senior Director of Downstream Marketing & Communications is Debra Rock. Ms. Rock is an experienced marketing and communications professional, having served in leadership positions in both the human and animal health industries. This experience includes roles at both AngioDynamics, a leading provider of minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology, and Pet Partners, where she oversaw the marketing efforts of a veterinary practice company with more than sixty affiliated hospitals of varying sizes and specialties located throughout the United States. Ms. Rock holds a B.A. in Communications from Brigham Young University and an MBA in Marketing from the State University of New York at Albany.
Ms. Rock joins Mike Schilk and Bonnie Bragdon at Zomedica. Mr. Schilk, Vice President of Sales, has demonstrated medical sales leadership over the past twenty-five years first at Pfizer Inc., then at Abbott Laboratories where he was responsible for the growth and development of more than 100 sales professionals and managers serving a $300 million business unit, followed by positions as Vice President of Sales & Business Development at I4cInnovations and General Manager US & International Endodontics at SS White Dental. Mr. Schilk joined Zomedica in 2018, and has been essential in building the internal sales organization in anticipation of the commercial release of TRUFORMA™.
Dr. Bragdon joined Zomedica in 2019 as Vice President of Veterinary Affairs. Dr. Bragdon is a licensed veterinarian, having earned her Doctorate of Veterinary Medicine & Master of Science, as well as a Master of Veterinary Clinical Science, from The Ohio State University. Her more than twenty years of experience in the animal health profession includes practicing as a veterinarian, followed by positions of increasing responsibility at Abbott Animal Health (acquired by Zoetis), BonVet Animal Health, and Merck Animal Health. Ms. Bragdon has made significant contributions to both the veterinary affairs and marketing capabilities of Zomedica surrounding the development of TRUFORMA.
“I could not be more pleased to have such a capable and experienced team of professionals leading our commercialization efforts,” commented Brük Herbst, Chief Commercial Officer of Zomedica. “Bonnie and Mike have proven invaluable during their time at Zomedica in preparing a first-class plan surrounding TRUFORMA. As we move into 2021 and the anticipated launch of our first product at the end of March, I have complete confidence in Bonnie, Mike and Deb’s capabilities to lead us to commercial success.”
Protected by approximately 70 issued and pending patents, the TRUFORMA diagnostic platform uses Bulk Acoustic Wave (“BAW”) technology, developed by Qorvo (NASDAQ: QRVO), to provide a non-optical and fluorescence-free detection system for use at the point-of-care. BAW technology, also used in cell phones and in the world’s most advanced radar and communications systems, is an extremely reliable and precise technology. Zomedica expects to begin commercial sales of TRUFORMA on March 30, 2021.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica’s mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
- Email Alerts: http://investors.zomedica.com
- LinkedIn: https://www.linkedin.com/company/zomedica
- Facebook: https://www.facebook.com/zomedica/
- Twitter: https://twitter.com/zomedica
Reader Advisory
Except for statements of historical fact, this news release contains certain “forward-looking information” or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur and include statements relating to our expectations regarding the public offering. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts; uncertainty as to our ability to supply equipment and assays in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of our obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
PCG Advisory
Kirin Smith, President
ksmith@pcgadvisory.com
+1 646.863.6519
